MRK, Daiichi's BLA for ADC Drug Gets FDA Priority Tag in Lung Cancer

The FDA accepted Merck and Daiichi Sankyo’s BLA for ifinatamab deruxtecan (I-DXd) with priority review, with a decision expected on Oct. 10, 2026. If approved, it would be the first B7-H3-directed DXd ADC for ES-SCLC patients whose disease progressed after platinum chemotherapy. The application is supported by phase II IDeate-Lung01 data and the stock has risen 14.1% year to date.

Analysis

The market should view this as an incremental de-risking event for MRK rather than a true binary re-rate. Priority review plus Orbis materially shortens the path to launch, but the bigger signal is that Merck is trying to build a differentiated oncology franchise outside the crowded PD-1/COVID-era cash engine; that matters because investors will eventually value MRK on its ability to replace Keytruda-era concentration with a portfolio of multi-indication assets. The first-order upside is modest, but the second-order effect is more important: if I-DXd gets approved, it validates Merck's willingness to pay for late-stage oncology assets and reduces skepticism around the Daiichi collaboration economics.

Competitive dynamics favor Daiichi's ADC platform more than the broad oncology peers. A first-in-class B7-H3 label would increase physician willingness to sequence ADCs earlier in the refractory SCLC setting, which could pressure smaller lung-cancer developers and raise the bar for any competing DLL3 or TROP2 programs trying to enter later. The read-through for AZN is mixed: its own ADC franchise is still the category leader, but a successful Merck/Daiichi launch would reinforce that the next wave of oncology growth is increasingly platform-driven, not single-asset-driven, and could accelerate BD spending across the sector.

The key risk is not FDA acceptance; it is commercial durability. ES-SCLC is clinically desperate but commercially tricky: rapid progression, poor performance status, and heterogeneous prior therapy exposure can cap duration of treatment and real-world uptake, so the revenue opportunity may be narrower than the headline enthusiasm suggests. Over the next 6-18 months, the main reversal catalysts are an adverse confirmatory data readout, weaker-than-expected label breadth, or safety signals that restrict sequencing versus existing topoisomerase-based regimens.

Consensus likely underestimates how much of MRK's near-term upside is already in the stock after a 14% YTD move. This event supports the multiple more than it expands earnings, so the trade is less about chasing the headline and more about owning optionality into the decision date while fading overbought enthusiasm if the stock outruns fundamentals. PFE is the cleaner relative loser if investors start rotating capital toward ADC franchises with stronger late-stage catalysts and clearer platform visibility.

Key Decisions for Investors

• Stay long MRK into the Oct. 10, 2026 PDUFA, but size it as an optionality trade rather than a core fundamental addition; risk/reward is favorable if the market assigns even a modest launch probability, but upside is capped unless label breadth surprises to the positive.
• Sell upside on MRK strength via 6-12 month call spreads into pre-decision rallies; the stock already reflects some pipeline optimism, so implied upside into approval may be better monetized than chased.
• Go long AZN on dips versus PFE as a cleaner ADC-platform relative value expression; AZN has the most de-risked commercial ADC footprint, while PFE's Seagen assets are mature and less likely to reaccelerate on this catalyst.
• Pair trade: long MRK / short a smaller-cap oncology name with direct SCLC exposure if available in the basket, to capture approval optionality while hedging away broad market beta; the thesis is that a first-in-class label will compress dispersion inside refractory lung cancer.
• For a higher-conviction catalyst trade, buy MRK Jan-2027 call spreads only on post-news pullbacks; timing matters because the current move is driven by regulatory process, not earnings revisions, so entry on weakness offers a better skew.